Skip to content
Screener

McKesson MCK Prescription Technology Solutions — Restructuring Charges

Other segment segments

North American Pharmaceutical
$16M
Medical-Surgical Solutions
$10M-71.4%

Similar metrics at other companies

Henry Schein logo
HSICGlobal Technology — Restructuring Charges
$2M0.0%
Kelly Services logo
KELYBScience, Engineering & Technology — Restructuring Charges
$300K-72.7%
Helmerich & Payne logo
HPInternational Solutions — Restructuring Charges
$302K-75.6%
Helmerich & Payne logo
HPOffshore Solutions — Restructuring Charges
$0
Vishay Precision Group logo
VPGWeighing Solutions — Restructuring Charges
$7K-89.9%
TE Connectivity logo
TELTransportation Solutions — Restructuring Charges
$1M-97.0%

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$100.24B+9.1%
Enterprise value$98.54B-2.2%
P/E21.1×-8.0×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The source filing: McKesson’s 10-K, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal year
FY2026
Accession
0000927653-26-000069
(In millions)Year Ended March 31, 2026 / North American Pharmaceutical (1)Year Ended March 31, 2026 / Prescription Technology Solutions (2)Year Ended March 31, 2026 / Medical-Surgical Solutions (3)Year Ended March 31, 2026 / Corporate & Other (4)Total
Severance and employee-related costs, net$9$3$14$(1)$25
Exit and other-related costs (5)337151191
Asset impairments and accelerated depreciation1217(8)829
Total$24$20$43$158$245

Item 8. Financial Statements and Supplementary Data.

FAQ

What is McKesson's prescription technology solutions — restructuring charges?
McKesson (MCK) reported prescription technology solutions — restructuring charges of $20M in Q1 2026.
How has McKesson's prescription technology solutions — restructuring charges changed year-over-year?
McKesson's prescription technology solutions — restructuring charges increased by 185.7% year-over-year, from $7M to $20M.
What is the long-term trend for McKesson's prescription technology solutions — restructuring charges?
Over 4 years (2022 to 2026), McKesson's prescription technology solutions — restructuring charges has grown at a -5.4% compound annual growth rate (CAGR), from $25M to $20M.
What does prescription technology solutions — restructuring charges mean?
Aggregates all costs associated with formal restructuring programs designed to improve the profitability and operational structure of the Prescription Technology Solutions segment. This includes costs for process re-engineering, organizational realignment, and other strategic transformation efforts.

Ask your AI about McKesson's prescription technology solutions — restructuring charges.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude